Brief: Atea Pharmaceuticals Presents Preclinical Results Of At-587
24/02/2026 12:14
Feb 24 (Reuters) - Atea Pharmaceuticals Inc AVIR.O :
* ATEA PHARMACEUTICALS PRESENTS PRECLINICAL RESULTS
SUPPORTING
FIRST-IN-CLASS POTENTIAL OF AT-587 FOR TREATMENT OF HEPATITIS E
VIRUS AT CROI 2026
Source text: ID:nGNX80b25W
Further company coverage: AVIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM